Novo is expanding its direct-to-consumer efforts around its obesity drug Wegovy, partnering with telehealth companies ...

From a fundamental standpoint, Eli Lilly presently has a market capitalization of $789 billion. Over the trailing twelve ...

Pfizer Inc. is cutting at least another $1.2 billion from its spending while the company searches for its next big hit after ...

With GLP-1 shortage officially over, patients who relied on compounded copies have only bad options to choose from ...

Deals with Hims & Hers, LifeMD and Ro following a court's dismissal of a lawsuit challenging the FDA's determination Wegovy ...

Disparities in prescribing semaglutide and tirzepatide for obesity reveal social factors affecting access and highlight the ...

Novo Nordisk said on Tuesday it was partnering with telehealth firms Hims & Hers , Ro and LifeMD to sell branded versions of ...

On Friday, Mad Money host Jim Cramer took a close look at what he called one of the most important stretches of the earnings ...

Wegovy and Zepbound, the two leading weight-loss drugs, together sold less than $5 billion in 2023, according to ...

The NBA Hall of Famer joined forces with the telehealth platform to restart his weight loss journey and raise awareness about ...

Hims & Hers ( HIMS) stock popped more than 20% in trading early Tuesday after Novo Nordisk ( NVO) announced a partnership with it and other telehealth platforms to offer patients access to the ...

Novo Nordisk appears to be letting compounded GLP-1 bygones be bygones—at least, in one respect. | Novo Nordisk appears to be ...